278 related articles for article (PubMed ID: 17956715)
21. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ
J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793
[No Abstract] [Full Text] [Related]
22. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
Missotten G; Verheezen Y
Bull Soc Belge Ophtalmol; 2010; (315):23-4. PubMed ID: 21110506
[TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
24. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
Frei M; Bornstein MM; Schaller B; Reichart PA; Weimann R; Iizuka T
J Oral Maxillofac Surg; 2010 Apr; 68(4):863-7. PubMed ID: 20307770
[No Abstract] [Full Text] [Related]
26. [Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
Lebret T; Mouysset JL; Lortholary A; Kouri CE; Bastit L; Ktiouet M; Khemaies S; Murraciole X; Guérif S
Bull Cancer; 2013 Mar; 100(3):247-57. PubMed ID: 23518272
[TBL] [Abstract][Full Text] [Related]
27. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid in metastatic bone disease: an audit based discussion.
Akbar RA; Gosh SK; Khalil S; ul Haq SM
J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
[TBL] [Abstract][Full Text] [Related]
29. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
30. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
31. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
32. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
Epperla N; Pathak R
WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
34. Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Vogelgesang SA; McMillin JM
J Urol; 1988 Nov; 140(5):1025-7. PubMed ID: 3172354
[TBL] [Abstract][Full Text] [Related]
35. Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Jun JH
Korean J Ophthalmol; 2017 Aug; 31(4):368-369. PubMed ID: 28682020
[No Abstract] [Full Text] [Related]
36. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Crawford BS; McNulty RM; Kraut EH; Turowski RC
Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
[TBL] [Abstract][Full Text] [Related]
37. Long interval zoledronic acid use in bone metastases.
Das M
Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632
[No Abstract] [Full Text] [Related]
38. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
39. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
40. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
